lipid modifying agents	are	drugs
lipid modifying agents	treat	hyperlipidemia
lipid modifying agents	lower	LDL‑cholesterol
lipid modifying agents	lower	triglycerides
lipid modifying agents	raise	HDL‑cholesterol
lipid modifying agents	reduce	cardiovascular risk
lipid modifying agents	include	statins
lipid modifying agents	include	fibrates
lipid modifying agents	include	niacin
lipid modifying agents	include	bile acid sequestrants
lipid modifying agents	include	PCSK9 inhibitors
lipid modifying agents	include	omega‑3 fatty acids
statins	inhibit	HMG‑CoA reductase
statins	cause	myopathy
statins	cause	hepatotoxicity
statins	are	first‑line therapy
fibrates	activate	PPAR‑α
fibrates	treat	hypertriglyceridemia
fibrates	cause	gallstones
niacin	raise	HDL‑cholesterol
niacin	cause	flushing
bile acid sequestrants	bind	bile acids
bile acid sequestrants	reduce	LDL‑cholesterol
PCSK9 inhibitors	inhibit	PCSK9
PCSK9 inhibitors	lower	LDL‑cholesterol
PCSK9 inhibitors	are	monoclonal antibodies
omega‑3 fatty acids	reduce	triglycerides
omega‑3 fatty acids	may reduce	arrhythmia
lipid modifying agents	are	prescription drugs
lipid modifying agents	are	over‑the‑counter drugs
lipid modifying agents	are	combination therapies
lipid modifying agents	are	monotherapy options
lipid modifying agents	are	adjunctive therapies
lipid modifying agents	are	cardiovascular prevention
lipid modifying agents	are	metabolic syndrome treatment
lipid modifying agents	are	atherosclerosis treatment
lipid modifying agents	are	statin‑resistant therapy
lipid modifying agents	are	statin‑intolerant therapy
lipid modifying agents	are	drug‑drug interaction risk
lipid modifying agents	are	dose‑dependent
lipid modifying agents	are	monitored by lipid panel
lipid modifying agents	are	monitored by liver enzymes
lipid modifying agents	are	monitored by creatine kinase
lipid modifying agents	are	monitored by renal function
lipid modifying agents	are	monitored by pregnancy category
lipid modifying agents	are	monitored by age group
lipid modifying agents	are	monitored by comorbidities
lipid modifying agents	are	monitored by adherence
lipid modifying agents	are	monitored by side‑effect profile
lipid modifying agents	are	monitored by cost
lipid modifying agents	are	monitored by insurance coverage
lipid modifying agents	are	monitored by patient education
lipid modifying agents	are	monitored by lifestyle modification
lipid modifying agents	are	monitored by diet
lipid modifying agents	are	monitored by exercise
lipid modifying agents	are	monitored by smoking cessation
lipid modifying agents	are	monitored by weight loss
lipid modifying agents	are	monitored by glycemic control
lipid modifying agents	are	monitored by blood pressure
lipid modifying agents	are	monitored by medication reconciliation
lipid modifying agents	are	monitored by patient‑reported outcomes
lipid modifying agents	are	monitored by clinical guidelines
lipid modifying agents	are	monitored by risk calculators
lipid modifying agents	are	monitored by statin‑intolerance protocols
lipid modifying agents	are	monitored by drug‑interaction databases
lipid modifying agents	are	monitored by pharmacogenomics
lipid modifying agents	are	monitored by therapeutic drug monitoring
lipid modifying agents	are	monitored by patient‑specific factors
lipid modifying agents	are	monitored by adverse event reporting
lipid modifying agents	are	monitored by clinical trials
lipid modifying agents	are	monitored by post‑marketing surveillance
lipid modifying agents	are	monitored by health‑system quality metrics
lipid modifying agents	are	monitored by electronic health records
lipid modifying agents	are	monitored by pharmacy benefit managers
lipid modifying agents	are	monitored by patient‑centered care
lipid modifying agents	are	monitored by shared decision making
lipid modifying agents	are	monitored by cost‑effectiveness analysis
lipid modifying agents	are	monitored by population health
lipid modifying agents	are	monitored by health‑care disparities
lipid modifying agents	are	monitored by quality improvement
lipid modifying agents	are	monitored by clinical decision support
lipid modifying agents	are	monitored by guideline adherence
lipid modifying agents	are	monitored by patient satisfaction
lipid modifying agents	are	monitored by medication adherence
lipid modifying agents	are	monitored by refill rates
lipid modifying agents	are	monitored by pharmacy counseling
lipid modifying agents	are	monitored by nurse‑led interventions
lipid modifying agents	are	monitored by pharmacist‑led interventions
lipid modifying agents	are	monitored by multidisciplinary teams
lipid modifying agents	are	monitored by telehealth
lipid modifying agents	are	monitored by remote monitoring
lipid modifying agents	are	monitored by patient portals
lipid modifying agents	are	monitored by clinical registries
lipid modifying agents	are	monitored by health‑care analytics
lipid modifying agents	are	monitored by predictive modeling
lipid modifying agents	are	monitored by machine learning
lipid modifying agents	are	monitored by artificial intelligence
lipid modifying agents	are	monitored by big data
lipid modifying agents	are	monitored by real‑world evidence
lipid modifying agents	are	monitored by patient‑reported outcomes
